The new treatment for seopositive patients will be administered at the Mayo Clinic in Minnesota next month.
The Mayo Clinic announced Wednesday that the seo-analogous therapy, developed by Dr. J. Michael Biederman, will begin in April.
“The treatment was originally developed to treat a group of patients who are unable to receive a traditional angiogram, a small X-ray machine, or any other diagnostic tests for septicemia,” said Mayo Clinic Director of Medicine, Dr. John R. Pritzker.
“It’s very important to us to give them the best possible treatment.”
The Mayo-led research program is funded by a $6.7 million grant from the National Institutes of Health (NIH).
The therapy is expected to take 10 to 15 years to complete.
“We are grateful to the Mayo family for their ongoing support of this project,” Dr. Biedeman said in a statement.
The Mayo study was the first of its kind in the United States, according to Mayo Clinic spokesperson Stephanie Gullickson.
Seopositors are those patients with septic shock and are treated with a combination of steroids and antibiotics.
Dr. Bagederman says that the treatment is designed to give patients the chance to “come back to normal” without the risk of a relapse.
The treatment has been used for more than a decade, but is still a relatively new treatment option.
“The initial results showed a significantly higher rate of re-hospitalization for patients who received the treatment compared to those who received antibiotics,” Dr Biedermans said.
“As we were working to determine the effectiveness of the treatment, we began to realize that this was not a drug that would be effective for patients.
Instead, we were looking for a treatment that would provide the patients with a chance to come back to a normal state.”
The goal of the Mayo-designed therapy is to help patients with mild to moderate septic infections who are not able to have a traditional MRI.
The Mayo Clinic has said it will not prescribe the therapy for any patients with severe sepsis or those with other severe septic disorders.